COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Authors
CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP, A. A. CABRERO, M. ANDRES, D. ANTIC, M. BAILE, P. BALIAKAS, D. BRON, A. CAPASSO, S. CHATZILEONTIADOU, R. CORDOBA, J.G. CORREA, C. CUELLAR-GARCIA, L. DE PAOLI, M. R. DE PAOLIS, G. DEL POETA, C. DEMOSTHENOUS, M. DIMOU, D. DONALDSON, Michael DOUBEK (203 Czech Republic, belonging to the institution), M. EFSTATHOPOULOU, B. EICHHORST, S. EL-ASHWAH, A. ENRICO, B. ESPINET, L. FARINA, A. FERRARI, M. FOGLIETTA, H. FREDERIKSEN, M. FURSTENAU, J. A. GARCIA-MARCO, R. GARCIA-SERRA, M. GENTILE, E. GIMENO, A. GLENTHOJ, M. G. DA SILVA, O. GUTWEIN, Y. K. HAKOBYAN, Y. HERISHANU, J. A. HERNANDEZ-RIVAS, T. HEROLD, I. INNOCENTI, G. ITCHAKI, O. JAKSIC, A. JANSSENS, O. B. KALASHNIKOVA, E. KALICINSKA, L. K. KARLSSON, A. P. KATER, S. KERSTING, J. LABRADOR, D. LAD, L. LAURENTI, M. D. LEVIN, E. LISTA, A. LOPEZ-GARCIA, L. MALERBA, R. MARASCA, M. MARCHETTI, J. MARQUET, M. MATTSSON, F. R. MAURO, I. MILOSEVIC, F. MIRAS, M. MORAWSKA, M. MOTTA, T. MUNIR, R. MURRU, C. U. NIEMANN, R. N. RODRIGUES, J. OLIVIERI, L. ORSUCCI, M. PAPAIOANNOU, M. A. PAVLOVSKY, I. PISKUNOVA, V. M. POPOV, F. M. QUAGLIA, G. QUARESMINI, K. QVIST, G. REDA, G. M. RIGOLIN, R. RUCHLEMER, G. SAGHUMYAN, A. SHRESTHA, M. SIMKOVIC, M. SPACEK, P. SPORTOLETTI, O. STANCA, N. STAVROYIANNI, T. TADMOR, D. TE RAA, S. H. TONINO, L. TRENTIN, E. VAN DER SPEK, M. VAN GELDER, R. VAN KAMPEN, M. VARETTONI, A. VISENTIN, C. VITALE, E. WASIK-SZCZEPANEK, T. WROBEL, L. Y. SAN SEGUNDO, M. YASSIN, M. COSCIA, A. RAMBALDI, E. MONTSERRAT, R. FOA, A. CUNEO, K. STAMATOPOULOS and P. GHIA
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP, A. A. CABRERO, M. ANDRES, D. ANTIC, M. BAILE, P. BALIAKAS, D. BRON, A. CAPASSO, S. CHATZILEONTIADOU, R. CORDOBA, J.G. CORREA, C. CUELLAR-GARCIA, L. DE PAOLI, M. R. DE PAOLIS, G. DEL POETA, C. DEMOSTHENOUS, M. DIMOU, D. DONALDSON, Michael DOUBEK, M. EFSTATHOPOULOU, B. EICHHORST, S. EL-ASHWAH, A. ENRICO, B. ESPINET, L. FARINA, A. FERRARI, M. FOGLIETTA, H. FREDERIKSEN, M. FURSTENAU, J. A. GARCIA-MARCO, R. GARCIA-SERRA, M. GENTILE, E. GIMENO, A. GLENTHOJ, M. G. DA SILVA, O. GUTWEIN, Y. K. HAKOBYAN, Y. HERISHANU, J. A. HERNANDEZ-RIVAS, T. HEROLD, I. INNOCENTI, G. ITCHAKI, O. JAKSIC, A. JANSSENS, O. B. KALASHNIKOVA, E. KALICINSKA, L. K. KARLSSON, A. P. KATER, S. KERSTING, J. LABRADOR, D. LAD, L. LAURENTI, M. D. LEVIN, E. LISTA, A. LOPEZ-GARCIA, L. MALERBA, R. MARASCA, M. MARCHETTI, J. MARQUET, M. MATTSSON, F. R. MAURO, I. MILOSEVIC, F. MIRAS, M. MORAWSKA, M. MOTTA, T. MUNIR, R. MURRU, C. U. NIEMANN, R. N. RODRIGUES, J. OLIVIERI, L. ORSUCCI, M. PAPAIOANNOU, M. A. PAVLOVSKY, I. PISKUNOVA, V. M. POPOV, F. M. QUAGLIA, G. QUARESMINI, K. QVIST, G. REDA, G. M. RIGOLIN, R. RUCHLEMER, G. SAGHUMYAN, A. SHRESTHA, M. SIMKOVIC, M. SPACEK, P. SPORTOLETTI, O. STANCA, N. STAVROYIANNI, T. TADMOR, D. TE RAA, S. H. TONINO, L. TRENTIN, E. VAN DER SPEK, M. VAN GELDER, R. VAN KAMPEN, M. VARETTONI, A. VISENTIN, C. VITALE, E. WASIK-SZCZEPANEK, T. WROBEL, L. Y. SAN SEGUNDO, M. YASSIN, M. COSCIA, A. RAMBALDI, E. MONTSERRAT, R. FOA, A. CUNEO, K. STAMATOPOULOS and P. GHIA. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. London: Nature Publishing Group, 2021, vol. 35, No 12, p. 3444-3454. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01450-8.
@article{1824585, author = {Chatzikonstantinou, T. and Kapetanakis, A. and Scarfo, L. and Karakatsoulis, G. and Allsup, D. and Cabrero, A. A. and Andres, M. and Antic, D. and Baile, M. and Baliakas, P. and Bron, D. and Capasso, A. and Chatzileontiadou, S. and Cordoba, R. and Correa, J.G. and CuellarandGarcia, C. and De Paoli, L. and De Paolis, M. R. and Del Poeta, G. and Demosthenous, C. and Dimou, M. and Donaldson, D. and Doubek, Michael and Efstathopoulou, M. and Eichhorst, B. and ElandAshwah, S. and Enrico, A. and Espinet, B. and Farina, L. and Ferrari, A. and Foglietta, M. and Frederiksen, H. and Furstenau, M. and GarciaandMarco, J. A. and GarciaandSerra, R. and Gentile, M. and Gimeno, E. and Glenthoj, A. and da Silva, M. G. and Gutwein, O. and Hakobyan, Y. K. and Herishanu, Y. and HernandezandRivas, J. A. and Herold, T. and Innocenti, I. and Itchaki, G. and Jaksic, O. and Janssens, A. and Kalashnikova, O. B. and Kalicinska, E. and Karlsson, L. K. and Kater, A. P. and Kersting, S. and Labrador, J. and Lad, D. and Laurenti, L. and Levin, M. D. and Lista, E. and LopezandGarcia, A. and Malerba, L. and Marasca, R. and Marchetti, M. and Marquet, J. and Mattsson, M. and Mauro, F. R. and Milosevic, I. and Miras, F. and Morawska, M. and Motta, M. and Munir, T. and Murru, R. and Niemann, C. U. and Rodrigues, R. N. and Olivieri, J. and Orsucci, L. and Papaioannou, M. and Pavlovsky, M. A. and Piskunova, I. and Popov, V. M. and Quaglia, F. M. and Quaresmini, G. and Qvist, K. and Reda, G. and Rigolin, G. M. and Ruchlemer, R. and Saghumyan, G. and Shrestha, A. and Simkovic, M. and Spacek, M. and Sportoletti, P. and Stanca, O. and Stavroyianni, N. and Tadmor, T. and Te Raa, D. and Tonino, S. H. and Trentin, L. and Van der Spek, E. and van Gelder, M. and van Kampen, R. and Varettoni, M. and Visentin, A. and Vitale, C. and WasikandSzczepanek, E. and Wrobel, T. and San Segundo, L. Y. and Yassin, M. and Coscia, M. and Rambaldi, A. and Montserrat, E. and Foa, R. and Cuneo, A. and Stamatopoulos, K. and Ghia, P.}, article_location = {London}, article_number = {12}, doi = {http://dx.doi.org/10.1038/s41375-021-01450-8}, keywords = {COVID-19; severity; mortality; CLL}, language = {eng}, issn = {0887-6924}, journal = {Leukemia}, title = {COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study}, url = {https://www.scopus.com/record/display.uri?eid=2-s2.0-85118404639&origin=resultslist&sort=plf-f&src=s&st1=10.1038%2fs41375-021-01450-8&sid=8af2314188bd4ac74984055e591ef59e&sot=b&sdt=b&sl=31&s=DOI%2810.1038%2fs41375-021-01450-8%29&relpos=0&citeCnt=1&search}, volume = {35}, year = {2021} }
TY - JOUR ID - 1824585 AU - Chatzikonstantinou, T. - Kapetanakis, A. - Scarfo, L. - Karakatsoulis, G. - Allsup, D. - Cabrero, A. A. - Andres, M. - Antic, D. - Baile, M. - Baliakas, P. - Bron, D. - Capasso, A. - Chatzileontiadou, S. - Cordoba, R. - Correa, J.G. - Cuellar-Garcia, C. - De Paoli, L. - De Paolis, M. R. - Del Poeta, G. - Demosthenous, C. - Dimou, M. - Donaldson, D. - Doubek, Michael - Efstathopoulou, M. - Eichhorst, B. - El-Ashwah, S. - Enrico, A. - Espinet, B. - Farina, L. - Ferrari, A. - Foglietta, M. - Frederiksen, H. - Furstenau, M. - Garcia-Marco, J. A. - Garcia-Serra, R. - Gentile, M. - Gimeno, E. - Glenthoj, A. - da Silva, M. G. - Gutwein, O. - Hakobyan, Y. K. - Herishanu, Y. - Hernandez-Rivas, J. A. - Herold, T. - Innocenti, I. - Itchaki, G. - Jaksic, O. - Janssens, A. - Kalashnikova, O. B. - Kalicinska, E. - Karlsson, L. K. - Kater, A. P. - Kersting, S. - Labrador, J. - Lad, D. - Laurenti, L. - Levin, M. D. - Lista, E. - Lopez-Garcia, A. - Malerba, L. - Marasca, R. - Marchetti, M. - Marquet, J. - Mattsson, M. - Mauro, F. R. - Milosevic, I. - Miras, F. - Morawska, M. - Motta, M. - Munir, T. - Murru, R. - Niemann, C. U. - Rodrigues, R. N. - Olivieri, J. - Orsucci, L. - Papaioannou, M. - Pavlovsky, M. A. - Piskunova, I. - Popov, V. M. - Quaglia, F. M. - Quaresmini, G. - Qvist, K. - Reda, G. - Rigolin, G. M. - Ruchlemer, R. - Saghumyan, G. - Shrestha, A. - Simkovic, M. - Spacek, M. - Sportoletti, P. - Stanca, O. - Stavroyianni, N. - Tadmor, T. - Te Raa, D. - Tonino, S. H. - Trentin, L. - Van der Spek, E. - van Gelder, M. - van Kampen, R. - Varettoni, M. - Visentin, A. - Vitale, C. - Wasik-Szczepanek, E. - Wrobel, T. - San Segundo, L. Y. - Yassin, M. - Coscia, M. - Rambaldi, A. - Montserrat, E. - Foa, R. - Cuneo, A. - Stamatopoulos, K. - Ghia, P. PY - 2021 TI - COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study JF - Leukemia VL - 35 IS - 12 SP - 3444-3454 EP - 3444-3454 PB - Nature Publishing Group SN - 08876924 KW - COVID-19 KW - severity KW - mortality KW - CLL UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85118404639&origin=resultslist&sort=plf-f&src=s&st1=10.1038%2fs41375-021-01450-8&sid=8af2314188bd4ac74984055e591ef59e&sot=b&sdt=b&sl=31&s=DOI%2810.1038%2fs41375-021-01450-8%29&relpos=0&citeCnt=1&search N2 - Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated. ER -
CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP, A. A. CABRERO, M. ANDRES, D. ANTIC, M. BAILE, P. BALIAKAS, D. BRON, A. CAPASSO, S. CHATZILEONTIADOU, R. CORDOBA, J.G. CORREA, C. CUELLAR-GARCIA, L. DE PAOLI, M. R. DE PAOLIS, G. DEL POETA, C. DEMOSTHENOUS, M. DIMOU, D. DONALDSON, Michael DOUBEK, M. EFSTATHOPOULOU, B. EICHHORST, S. EL-ASHWAH, A. ENRICO, B. ESPINET, L. FARINA, A. FERRARI, M. FOGLIETTA, H. FREDERIKSEN, M. FURSTENAU, J. A. GARCIA-MARCO, R. GARCIA-SERRA, M. GENTILE, E. GIMENO, A. GLENTHOJ, M. G. DA SILVA, O. GUTWEIN, Y. K. HAKOBYAN, Y. HERISHANU, J. A. HERNANDEZ-RIVAS, T. HEROLD, I. INNOCENTI, G. ITCHAKI, O. JAKSIC, A. JANSSENS, O. B. KALASHNIKOVA, E. KALICINSKA, L. K. KARLSSON, A. P. KATER, S. KERSTING, J. LABRADOR, D. LAD, L. LAURENTI, M. D. LEVIN, E. LISTA, A. LOPEZ-GARCIA, L. MALERBA, R. MARASCA, M. MARCHETTI, J. MARQUET, M. MATTSSON, F. R. MAURO, I. MILOSEVIC, F. MIRAS, M. MORAWSKA, M. MOTTA, T. MUNIR, R. MURRU, C. U. NIEMANN, R. N. RODRIGUES, J. OLIVIERI, L. ORSUCCI, M. PAPAIOANNOU, M. A. PAVLOVSKY, I. PISKUNOVA, V. M. POPOV, F. M. QUAGLIA, G. QUARESMINI, K. QVIST, G. REDA, G. M. RIGOLIN, R. RUCHLEMER, G. SAGHUMYAN, A. SHRESTHA, M. SIMKOVIC, M. SPACEK, P. SPORTOLETTI, O. STANCA, N. STAVROYIANNI, T. TADMOR, D. TE RAA, S. H. TONINO, L. TRENTIN, E. VAN DER SPEK, M. VAN GELDER, R. VAN KAMPEN, M. VARETTONI, A. VISENTIN, C. VITALE, E. WASIK-SZCZEPANEK, T. WROBEL, L. Y. SAN SEGUNDO, M. YASSIN, M. COSCIA, A. RAMBALDI, E. MONTSERRAT, R. FOA, A. CUNEO, K. STAMATOPOULOS and P. GHIA. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. \textit{Leukemia}. London: Nature Publishing Group, 2021, vol.~35, No~12, p.~3444-3454. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01450-8.